Cover Image
Market Research Report

EUROPE BETA GLUCAN MARKET FORECAST 2018-2026

Published by Inkwood Research Product code 636635
Published Content info 98 Pages
Delivery time: 1-2 business days
Price
Back to Top
EUROPE BETA GLUCAN MARKET FORECAST 2018-2026
Published: May 14, 2018 Content info: 98 Pages
Description

KEY FINDINGS

Europe beta glucan market has its primary application in food & beverages sector, pharmaceutical sector, animal feed and the personal care sector. As a result, the market is expected to rise with a CAGR of 7.29% over the forecast period of 2018-2026. European markets like UK, Germany, Spain, Italy, France and rest of Europe are covered in this report.

MARKET INSIGHTS

High demand for packaged foods and increasing prevalence of packaged foods are driving the beta-glucan market demand in the UK. The France beta glucan market is expanding due to increasing demand from the pharmaceutical sector while the German market is being propelled by its cosmetics and personal care sector. The growing prevalence of Cancer in the overall European market too is acting as a critical factor in enhancing the market demand. According to European Commission, Cancer has become the leading cause of death in European Union over the last decade (2007-2017). Beta-glucans can be used intravenously to treat various forms of cancers and boost the immune system of individuals.

COMPETITIVE INSIGHTS

Major market players like Specialty Biotech Ltd, Lesaffre Human Care, Cargill Inc, Alltech Biotechnology, Pharmacon Asa, Ohly, Kemin Industries, Kerry Group Plc, Super Beta Glucan, Milliporesigma (Merck) and Tate & Lyle Plc are competing in this market.

Table of Contents
Product Code: 17078

Table of Contents

1. RESEARCH SCOPE

  • 1.1. STUDY GOALS
  • 1.2. SCOPE OF THE MARKET STUDY
  • 1.3. WHO WILL FIND THIS REPORT USEFUL?
  • 1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

  • 2.1. SOURCES OF DATA
    • 2.1.1. SECONDARY DATA
    • 2.1.2. PRIMARY DATA
  • 2.2. TOP DOWN APPROACH
  • 2.3. BOTTOM-UP APPROACH
  • 2.4. DATA TRIANGULATION
  • 2.5. ESTIMATION METHODOLOGY

3. EXECUTIVE SUMMARY

  • 3.1. MARKET SUMMARY
  • 3.2. KEY FINDINGS
    • 3.2.1. EUROPE HELD A COLOSSAL SHARE OF THE MARKET
    • 3.2.2. PHARMACEUTICAL- MAJOR MARKET BY END-USER
    • 3.2.3. SOLUBLE BETA GLUCAN HELD MAJOR CHUNK OF THE MARKET BY CATEGORY
    • 3.2.4. CEREALS TO OFFER LUCRATIVE OPPORTUNITIES

4. MARKET DYNAMICS

  • 4.1. MARKET DEFINITION
  • 4.2. DRIVERS
    • 4.2.1. GROWING HEALTH CONCERN AMONG CONSUMERS AND INCREASING HEALTH EXPENDITURE
    • 4.2.2. GROWING APPLICATIONS OF BETA-GLUCAN IN THE FOOD INDUSTRY
    • 4.2.3. DECREASING PRICES OF MAJOR RAW MATERIAL SOURCES
  • 4.3. RESTRAINTS
    • 4.3.1. VARIOUS SIDE EFFECTS OF CONSUMING BETA GLUCAN
    • 4.3.2. INCONSISTENCY IN REGULATORY NORMS
  • 4.4. OPPORTUNITIES
    • 4.4.1. UNEXPLOITED BETA GLUCAN APPLICATIONS IN COSMETIC AND MEDICINE SECTOR
  • 4.5. CHALLENGES
    • 4.5.1. INCREASE IN THE COST OF BETA-GLUCAN EXTRACTION PROCESS

5. MARKET BY SOURCE

  • 5.1. BACTERIA
  • 5.2. FUNGUS
  • 5.3. YEAST
  • 5.4. CEREAL
  • 5.5. ALGAE

6. MARKET BY END-USERS

  • 6.1. FOOD AND BEVERAGES
  • 6.2. PERSONAL CARE
  • 6.3. PHARMACEUTICALS
  • 6.4. ANIMAL FEED

7. MARKET BY CATEGORY

  • 7.1. INSOLUBLE BETA GLUCAN
  • 7.2. SOLUBLE BETA GLUCAN

8. KEY ANALYTICS

  • 8.1. PORTER'S 5 FORCE MODEL
    • 8.1.1. THREAT OF NEW ENTRANTS
    • 8.1.2. THREAT OF SUBSTITUTE PRODUCTS
    • 8.1.3. BARGAINING POWER OF BUYERS
    • 8.1.4. BARGAINING POWER OF SUPPLIERS
    • 8.1.5. INTENSITY OF COMPETITIVE RIVALRY
  • 8.2. KEY BUYING CRITERIA
    • 8.2.1. COST
    • 8.2.2. NUTRITIONAL CONTENT
    • 8.2.3. SOURCE
    • 8.2.4. APPLICATIONS
  • 8.3. VALUE CHAIN ANALYSIS
    • 8.3.1. RAW MATERIAL SUPPLIERS
    • 8.3.2. MANUFACTURING
    • 8.3.3. DISTRIBUTORS/RETAILERS
    • 8.3.4. END-USERS
  • 8.4. REGULATORY FRAMEWORK
  • 8.5. KEY TRENDS
    • 8.5.1. RISING PREVALENCE OF DIABETES
    • 8.5.2. INVESTMENTS IN BETA GLUCAN
  • 8.6. INVESTMENT OUTLOOK
    • 8.6.1. END-USERS OUTLOOK
  • 8.7. VENDOR LANDSCAPE
  • 8.8. OPPORTUNITY MATRIX

9. GEOGRAPHICAL ANALYSIS

  • 9.1. UK
  • 9.2. FRANCE
  • 9.3. GERMANY
  • 9.4. ITALY
  • 9.5. SPAIN
  • 9.6. REST OF EUROPE

10. COMPETITIVE LANDSCAPE

  • 10.1. MARKET SHARE ANALYSIS
    • 10.1.1. CARGILL INC (US)
    • 10.1.2. TATE & LYLE (UK)
    • 10.1.3. KERRY GROUP PLC (ISRAEL)
    • 10.1.4. OHLY (GERMANY)
    • 10.1.5. KONINKLIJKE DSM N.V. (NETHERLANDS)
  • 10.2. COMPANY PROFILES
    • 10.2.1. ALLTECH BIOTECHNOLOGY
      • 10.2.1.1. OVERVIEW
      • 10.2.1.2. PRODUCT PORTFOLIO
      • 10.2.1.3. SCOT ANALYSIS
      • 10.2.1.4. STRATEGIC ANALYSIS
    • 10.2.2. CARGILL INC
      • 10.2.2.1. OVERVIEW
      • 10.2.2.2. PRODUCT PORTFOLIO
      • 10.2.2.3. SCOT ANALYSIS
      • 10.2.2.4. STRATEGIC ANALYSIS
    • 10.2.3. CHR. HANSEN A/S
      • 10.2.3.1. OVERVIEW
      • 10.2.3.2. PRODUCT PORTFOLIO
      • 10.2.3.3. SCOT ANALYSIS
      • 10.2.3.4. STRATEGIC ANALYSIS
    • 10.2.4. GARUDA INTERNATIONAL INC
      • 10.2.4.1. OVERVIEW
      • 10.2.4.2. PRODUCT PORTFOLIO
      • 10.2.4.3. SCOT ANALYSIS
      • 10.2.4.4. STRATEGIC ANALYSIS
    • 10.2.5. KEMIN INDUSTRIES
      • 10.2.5.1. OVERVIEW
      • 10.2.5.2. PRODUCT PORTFOLIO
      • 10.2.5.3. STRATEGIC INITIATIVES
      • 10.2.5.4. SCOT ANALYSIS
      • 10.2.5.5. STRATEGIC ANALYSIS
    • 10.2.6. SPECIALTY BIOTECH LTD
      • 10.2.6.1. OVERVIEW
      • 10.2.6.2. PRODUCT PORTFOLIO
      • 10.2.6.3. SCOT ANALYSIS
      • 10.2.6.4. STRATEGIC ANALYSIS
    • 10.2.7. MILLIPORESIGMA (MERCK)
      • 10.2.7.1. OVERVIEW
      • 10.2.7.2. PRODUCT PORTFOLIO
      • 10.2.7.3. SCOT ANALYSIS
      • 10.2.7.4. STRATEGIC ANALYSIS
    • 10.2.8. OHLY
      • 10.2.8.1. OVERVIEW
      • 10.2.8.2. PRODUCT PORTFOLIO
      • 10.2.8.3. STRATEGIC INITIATIVES
      • 10.2.8.4. SCOT ANALYSIS
      • 10.2.8.5. STRATEGIC ANALYSIS
    • 10.2.9. TATE & LYLE PLC
      • 10.2.9.1. OVERVIEW
      • 10.2.9.2. PRODUCT PORTFOLIO
      • 10.2.9.3. STRATEGIC INITIATIVES
      • 10.2.9.4. SCOT ANALYSIS
      • 10.2.9.5. STRATEGIC ANALYSIS
    • 10.2.10. SUPER BETA GLUCAN
      • 10.2.10.1. OVERVIEW
      • 10.2.10.2. PRODUCT PORTFOLIO
      • 10.2.10.3. SCOT ANALYSIS
      • 10.2.10.4. STRATEGIC ANALYSIS
    • 10.2.11. KONINKLIJKE DSM N.V.
      • 10.2.11.1. OVERVIEW
      • 10.2.11.2. PRODUCT PORTFOLIO
      • 10.2.11.3. SCOT ANALYSIS
      • 10.2.11.4. STRATEGIC ANALYSIS
    • 10.2.12. FRUTAROM
      • 10.2.12.1. OVERVIEW
      • 10.2.12.2. PRODUCT PORTFOLIO
      • 10.2.12.3. SCOT ANALYSIS
      • 10.2.12.4. STRATEGIC ANALYSIS
    • 10.2.13. KERRY GROUP PLC
      • 10.2.13.1. OVERVIEW
      • 10.2.13.2. PRODUCT PORTFOLIO
      • 10.2.13.3. STRATEGIC ANALYSIS
      • 10.2.13.4. SCOT ANALYSIS
      • 10.2.13.5. STRATEGIC ANALYSIS
    • 10.2.14. LESAFFRE HUMAN CARE
      • 10.2.14.1. OVERVIEW
      • 10.2.14.2. PRODUCT PORTFOLIO
      • 10.2.14.3. SCOT ANALYSIS
      • 10.2.14.4. STRATEGIC ANALYSIS
    • 10.2.15. PHARMACON ASA
      • 10.2.15.1. OVERVIEW
      • 10.2.15.2. PRODUCT PORTFOLIO
      • 10.2.15.3. STRATEGIC INITIATIVES
      • 10.2.15.4. SCOT ANALYSIS
      • 10.2.15.5. STRATEGIC ANALYSIS

LIST OF TABLES

  • TABLE 1 EUROPE BETA GLUCAN MARKET BY COUNTRY 2018-2026 ($ MILLION)
  • TABLE 2 APPLICATIONS OF DIFFERENT BETA GLUCAN IN FOOD PRODUCTION
  • TABLE 3 EUROPE BETA GLUCAN MARKET BY SOURCE 2018-2026 ($ MILLION)
  • TABLE 4 EUROPE BETA GLUCAN MARKET BY END-USERS 2018-2026 ($ MILLION)
  • TABLE 5 EUROPE BETA GLUCAN MARKET BY CATEGORY 2018-2026 ($ MILLION)
  • TABLE 6 INVESTMENTS IN BETA GLUCAN
  • TABLE 7 EUROPE BETA GLUCAN MARKET BY COUNTRY 2018-2026 ($ MILLION)

LIST OF FIGURES

  • FIGURE 1 EUROPE BETA GLUCAN MARKET BY SOURCE 2018-2026 ($ MILLION)
  • FIGURE 2 EUROPE BETA GLUCAN MARKET 2018-2026 ($ MILLION)
  • FIGURE 3 EUROPE SOLUBLE BETA GLUCAN MARKET 2018-2026 ($ MILLION)
  • FIGURE 4 EUROPE CEREALS MARKET 2018-2026 ($ MILLION)
  • FIGURE 5 EVOLUTION OF BETA-GLUCAN MARKET
  • FIGURE 6 HEALTHCARE SPENDING PER CAPITA IN 2015 AND 2016
  • FIGURE 7 COMMODITY PRICE INDEX OF WHEAT CROPS
  • FIGURE 8 EU OAT PRICES IN 2015 (MAJOR COUNTRIES)
  • FIGURE 9 EUROPE COSMETICS PRODUCTS MARKET 2015 ($ BILLION)
  • FIGURE 10 EUROPE BACTERIA MARKET 2018-2026 ($ MILLION)
  • FIGURE 11 EUROPE FUNGUS MARKET 2018-2026 ($ MILLION)
  • FIGURE 12 EUROPE YEAST MARKET 2018-2026 ($ MILLION)
  • FIGURE 13 EUROPE CEREAL MARKET 2018-2026 ($ MILLION)
  • FIGURE 14 EUROPE ALGAE MARKET 2018-2026 ($ MILLION)
  • FIGURE 15 EUROPE FOOD AND BEVERAGES MARKET 2018-2026 ($ MILLION)
  • FIGURE 16 EUROPE PERSONAL CARE MARKET 2018-2026 ($ MILLION)
  • FIGURE 17 EUROPE PHARMACEUTICALS MARKET 2018-2026 ($ MILLION)
  • FIGURE 18 EUROPE ANIMAL FEED MARKET 2018-2026 ($ MILLION)
  • FIGURE 19 EUROPE INSOLUBLE BETA GLUCAN MARKET 2018-2026 ($ MILLION)
  • FIGURE 20 EUROPE SOLUBLE BETA GLUCAN MARKET 2018-2026 ($ MILLION)
  • FIGURE 21 TOP 10 COUNTRIES WITH NUMBER OF PEOPLE LIVING WITH DIABETES IN MILLION (2015)
  • FIGURE 22 PERCENTAGE INCREMENT OF DIABETES ACROSS REGIONS (2015 TO 2040)
  • FIGURE 23 INVESTMENT PROPOSITION FOR EUROPE BETA GLUCAN MARKET BY END-USERS - 2017
  • FIGURE 24 UNITED KINGDOM BETA GLUCAN MARKET 2018-2026 ($ MILLION)
  • FIGURE 25 FRANCE BETA GLUCAN MARKET 2018-2026 ($ MILLION)
  • FIGURE 26 GERMANY BETA GLUCAN MARKET 2018-2026 ($ MILLION)
  • FIGURE 27 ITALY BETA GLUCAN MARKET 2018-2026 ($ MILLION)
  • FIGURE 28 SPAIN BETA GLUCAN MARKET 2018-2026 ($ MILLION)
  • FIGURE 29 REST OF EUROPE BETA GLUCAN MARKET 2018-2026 ($ MILLION)
  • FIGURE 30 MARKET SHARE ANALYSIS OF TOP COMPANIES IN EUROPE BETA GLUCAN MARKET - 2017 (%)
Back to Top